human vegf elisa kit Search Results


93
Boster Bio human vegf vegfa elisa kit
Human Vegf Vegfa Elisa Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vegf+elisa+kit/pm41903748-82-13-17?v=Boster+Bio
Average 93 stars, based on 1 article reviews
human vegf vegfa elisa kit - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

95
Elabscience Biotechnology vegf a elsa kit
Vegf A Elsa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vegf+elisa+kit/pmc12180182-103-2-5?v=Elabscience+Biotechnology
Average 95 stars, based on 1 article reviews
vegf a elsa kit - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier

94
Diaclone human elisa kit
Human Elisa Kit, supplied by Diaclone, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vegf+elisa+kit/pmc05634974-67-3-2?v=Diaclone
Average 94 stars, based on 1 article reviews
human elisa kit - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

94
R&D Systems quantiglo chemiluminescent elisas humanvegf
Quantiglo Chemiluminescent Elisas Humanvegf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vegf+elisa+kit/pm37127039-58-7-12?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
quantiglo chemiluminescent elisas humanvegf - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

90
R&D Systems human vegf elisa kit
Changes in plasma vascular endothelial growth factor <t>(VEGF)</t> concentration in cats. †: The cat was euthanized because its clinical condition had reached the humane endpoint
Human Vegf Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vegf+elisa+kit/pmc07110289-65-8-12?v=R%26D+Systems
Average 90 stars, based on 1 article reviews
human vegf elisa kit - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

93
R&D Systems human vegf 165 elisa kit
Changes in plasma vascular endothelial growth factor <t>(VEGF)</t> concentration in cats. †: The cat was euthanized because its clinical condition had reached the humane endpoint
Human Vegf 165 Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vegf+elisa+kit/pmc02998412-141-28-33?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
human vegf 165 elisa kit - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

96
R&D Systems vascular endothelial growth factor
Nicotine-free e-cigarette condensate (eVape) exposure significantly increases angiogenic processes in human <t>endothelial</t> cells. (a) Human umbilical vein endothelial cells (HUVECs) were exposed to eVape fluid containing 0, 5, and 10 mg/mL of nicotine for 24 h at concentrations ranging from 0% to 2%. Cell viability was measured using the MTT assay, quantified at 570 nm, and calculated as percentage viability normalised to vehicle. (b, c) Endothelial cells were exposed to 2% eVape containing 0 mg/mL of nicotine or vascular endothelial growth factor <t>(VEGF;</t> 100 ng/mL) or vehicle control (H 2 O) for 6 h. (b) Cell adhesion was measured using MTT, while (c) cell migration was assessed using scratch assay and calculated with MiToBo. (d–g) Neovascularisation was measured by culturing cells treated with 2% eVape containing 0 mg/mL of nicotine or VEGF (100 ng/mL) or vehicle control (H 2 O) on Matrigel TM -coated wells. Images were captured at ×20 magnification (scale bar: 100 µm; representative images are shown in (d) ). (e) Angiogenic potential, (f) tube formation, and (g) mesh size were quantified as number of joints, number of tubes, and pixel size, respectively, using Angiogenesis Analyser. The data are presented as mean ± standard error of the mean (SEM), n = 5–6. * p < 0.05 versus vehicle for eVape (0%); # p < 0.05 versus vehicle for VEGF (0 ng/mL).
Vascular Endothelial Growth Factor, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vegf+elisa+kit/pmc12872546-37-41-51?v=R%26D+Systems
Average 96 stars, based on 1 article reviews
vascular endothelial growth factor - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier

93
Elabscience Biotechnology plasma human vegf
Nicotine-free e-cigarette condensate (eVape) exposure significantly increases angiogenic processes in human <t>endothelial</t> cells. (a) Human umbilical vein endothelial cells (HUVECs) were exposed to eVape fluid containing 0, 5, and 10 mg/mL of nicotine for 24 h at concentrations ranging from 0% to 2%. Cell viability was measured using the MTT assay, quantified at 570 nm, and calculated as percentage viability normalised to vehicle. (b, c) Endothelial cells were exposed to 2% eVape containing 0 mg/mL of nicotine or vascular endothelial growth factor <t>(VEGF;</t> 100 ng/mL) or vehicle control (H 2 O) for 6 h. (b) Cell adhesion was measured using MTT, while (c) cell migration was assessed using scratch assay and calculated with MiToBo. (d–g) Neovascularisation was measured by culturing cells treated with 2% eVape containing 0 mg/mL of nicotine or VEGF (100 ng/mL) or vehicle control (H 2 O) on Matrigel TM -coated wells. Images were captured at ×20 magnification (scale bar: 100 µm; representative images are shown in (d) ). (e) Angiogenic potential, (f) tube formation, and (g) mesh size were quantified as number of joints, number of tubes, and pixel size, respectively, using Angiogenesis Analyser. The data are presented as mean ± standard error of the mean (SEM), n = 5–6. * p < 0.05 versus vehicle for eVape (0%); # p < 0.05 versus vehicle for VEGF (0 ng/mL).
Plasma Human Vegf, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vegf+elisa+kit/10__21767_slash_2386___5180__1000107-52-12-17?v=Elabscience+Biotechnology
Average 93 stars, based on 1 article reviews
plasma human vegf - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

95
R&D Systems vegf elisa kit
Figure 2. Cytotoxicity of d‑2HG in BAECs. (A and B) BAECs were treated with various concentrations of d‑2HG (25 µM to 50 mM) for 24 h (A) or 48 h (B). Cell viability was measured by CCK‑8 assays. <t>VEGF</t> (40 ng/ml) was used as a positive control. *P<0.05 versus the control. BAECs, bovine aortic endothelial cells; d‑2HG, d‑2‑hydroxyglutarate; VEGF, vascular endothelial growth factor.
Vegf Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vegf+elisa+kit/pm30483760-72-20-23?v=R%26D+Systems
Average 95 stars, based on 1 article reviews
vegf elisa kit - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier

93
R&D Systems human vegf quantiglo elisa kit
FIG. 1. Morphometry of the anatomical zones analyzed in this study: VF, VH, main CST, DREZ, and CC. The gray field represents the area im- mediately around the <t>Ad5-VEGF+Ad5-ANG</t> or Ad5-GFP injections.
Human Vegf Quantiglo Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vegf+elisa+kit/10__3171_slash_2016__9__spine15959-59-37-42?v=R%26D+Systems
Average 93 stars, based on 1 article reviews
human vegf quantiglo elisa kit - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

97
R&D Systems human vegf a assay kit
FIG. 1. Morphometry of the anatomical zones analyzed in this study: VF, VH, main CST, DREZ, and CC. The gray field represents the area im- mediately around the <t>Ad5-VEGF+Ad5-ANG</t> or Ad5-GFP injections.
Human Vegf A Assay Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vegf+elisa+kit/pmc02493026-129-7-12?v=R%26D+Systems
Average 97 stars, based on 1 article reviews
human vegf a assay kit - by Bioz Stars, 2026-07
97/100 stars
  Buy from Supplier

Image Search Results


Changes in plasma vascular endothelial growth factor (VEGF) concentration in cats. †: The cat was euthanized because its clinical condition had reached the humane endpoint

Journal: Archives of Virology

Article Title: Therapeutic effect of an anti-human-TNF-alpha antibody and itraconazole on feline infectious peritonitis

doi: 10.1007/s00705-020-04605-7

Figure Lengend Snippet: Changes in plasma vascular endothelial growth factor (VEGF) concentration in cats. †: The cat was euthanized because its clinical condition had reached the humane endpoint

Article Snippet: Plasma concentrations of VEGF were determined using a human VEGF ELISA Kit (R & D Systems, Minneapolis, MN, USA), according to the manufacturer’s protocol.

Techniques: Clinical Proteomics, Concentration Assay

Nicotine-free e-cigarette condensate (eVape) exposure significantly increases angiogenic processes in human endothelial cells. (a) Human umbilical vein endothelial cells (HUVECs) were exposed to eVape fluid containing 0, 5, and 10 mg/mL of nicotine for 24 h at concentrations ranging from 0% to 2%. Cell viability was measured using the MTT assay, quantified at 570 nm, and calculated as percentage viability normalised to vehicle. (b, c) Endothelial cells were exposed to 2% eVape containing 0 mg/mL of nicotine or vascular endothelial growth factor (VEGF; 100 ng/mL) or vehicle control (H 2 O) for 6 h. (b) Cell adhesion was measured using MTT, while (c) cell migration was assessed using scratch assay and calculated with MiToBo. (d–g) Neovascularisation was measured by culturing cells treated with 2% eVape containing 0 mg/mL of nicotine or VEGF (100 ng/mL) or vehicle control (H 2 O) on Matrigel TM -coated wells. Images were captured at ×20 magnification (scale bar: 100 µm; representative images are shown in (d) ). (e) Angiogenic potential, (f) tube formation, and (g) mesh size were quantified as number of joints, number of tubes, and pixel size, respectively, using Angiogenesis Analyser. The data are presented as mean ± standard error of the mean (SEM), n = 5–6. * p < 0.05 versus vehicle for eVape (0%); # p < 0.05 versus vehicle for VEGF (0 ng/mL).

Journal: Frontiers in Toxicology

Article Title: Nicotine-free electronic vape fluid stimulates angiogenic processes in vitro through ARF6-mediated oxidative stress

doi: 10.3389/ftox.2025.1699112

Figure Lengend Snippet: Nicotine-free e-cigarette condensate (eVape) exposure significantly increases angiogenic processes in human endothelial cells. (a) Human umbilical vein endothelial cells (HUVECs) were exposed to eVape fluid containing 0, 5, and 10 mg/mL of nicotine for 24 h at concentrations ranging from 0% to 2%. Cell viability was measured using the MTT assay, quantified at 570 nm, and calculated as percentage viability normalised to vehicle. (b, c) Endothelial cells were exposed to 2% eVape containing 0 mg/mL of nicotine or vascular endothelial growth factor (VEGF; 100 ng/mL) or vehicle control (H 2 O) for 6 h. (b) Cell adhesion was measured using MTT, while (c) cell migration was assessed using scratch assay and calculated with MiToBo. (d–g) Neovascularisation was measured by culturing cells treated with 2% eVape containing 0 mg/mL of nicotine or VEGF (100 ng/mL) or vehicle control (H 2 O) on Matrigel TM -coated wells. Images were captured at ×20 magnification (scale bar: 100 µm; representative images are shown in (d) ). (e) Angiogenic potential, (f) tube formation, and (g) mesh size were quantified as number of joints, number of tubes, and pixel size, respectively, using Angiogenesis Analyser. The data are presented as mean ± standard error of the mean (SEM), n = 5–6. * p < 0.05 versus vehicle for eVape (0%); # p < 0.05 versus vehicle for VEGF (0 ng/mL).

Article Snippet: NAV2729 and Secin H3 were purchased from Tocris Bioscience (Abingdon, UK); Proteome Profiler Human angiogenesis array and enzyme-linked immunosorbent assay (ELISA) kits for human angiopoietin-2 (DANG20), endothelial growth factor (EGF; DEG00), endoglin (DNDG00), placental growth factor (PIGF; DPG00), prolactin (DY682), and vascular endothelial growth factor (VEGF; DVE00) were all obtained from R&D Systems (Abingdon, UK).

Techniques: MTT Assay, Control, Migration, Wound Healing Assay

Nicotine-free eVape exposure causes significant upregulation of angiopoietin-2, endoglin, placental growth factor (PIGF), and VEGF as well as significant downregulation of endothelial growth factor (EGF) and prolactin in endothelial cells. HUVECs were exposed to 2% nicotine-free eVape fluid for 24 h. (a–c) Cell lysates were used for the Proteome Profiler Angiogenesis array membranes. Changes in the expression of all angiogenesis-related proteins in array (a) (ii) were quantified using the membranes (representative image in (a) (i) ). Specific analyses of the (b) upregulation and (c) downregulation of angiogenesis-related proteins on the membranes were quantified. (d) mRNA expression of angiopoietin-2, EGF, endoglin, PIGF, prolactin, and VEGF were measured by RT-PCR using specific primers. (e) Protein expression of (i) angiopoietin-2, (ii) EGF, (iii) endoglin, (iv) PIGF, (v) prolactin, and (vi) VEGF were measured using specific ELISA arrays. The data are presented as mean ± SEM, n = 5–6. * p < 0.05 versus vehicle for eVape (0%).

Journal: Frontiers in Toxicology

Article Title: Nicotine-free electronic vape fluid stimulates angiogenic processes in vitro through ARF6-mediated oxidative stress

doi: 10.3389/ftox.2025.1699112

Figure Lengend Snippet: Nicotine-free eVape exposure causes significant upregulation of angiopoietin-2, endoglin, placental growth factor (PIGF), and VEGF as well as significant downregulation of endothelial growth factor (EGF) and prolactin in endothelial cells. HUVECs were exposed to 2% nicotine-free eVape fluid for 24 h. (a–c) Cell lysates were used for the Proteome Profiler Angiogenesis array membranes. Changes in the expression of all angiogenesis-related proteins in array (a) (ii) were quantified using the membranes (representative image in (a) (i) ). Specific analyses of the (b) upregulation and (c) downregulation of angiogenesis-related proteins on the membranes were quantified. (d) mRNA expression of angiopoietin-2, EGF, endoglin, PIGF, prolactin, and VEGF were measured by RT-PCR using specific primers. (e) Protein expression of (i) angiopoietin-2, (ii) EGF, (iii) endoglin, (iv) PIGF, (v) prolactin, and (vi) VEGF were measured using specific ELISA arrays. The data are presented as mean ± SEM, n = 5–6. * p < 0.05 versus vehicle for eVape (0%).

Article Snippet: NAV2729 and Secin H3 were purchased from Tocris Bioscience (Abingdon, UK); Proteome Profiler Human angiogenesis array and enzyme-linked immunosorbent assay (ELISA) kits for human angiopoietin-2 (DANG20), endothelial growth factor (EGF; DEG00), endoglin (DNDG00), placental growth factor (PIGF; DPG00), prolactin (DY682), and vascular endothelial growth factor (VEGF; DVE00) were all obtained from R&D Systems (Abingdon, UK).

Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay

Activation of ARF6 by its guanine nucleotide exchange factor (ARNO) regulates angiogenic processes in endothelial cells induced by nicotine-free eVape. (a, b) HUVECs were exposed to 2% nicotine-free eVape fluid for 24 h, and the cell lysates were analysed by Western blotting for (a) ARF6 or (b) ARNO expression. The Western blotting membranes (representative blots are shown in (i) ) were quantified and normalised to the actin expression shown in (ii) . (c–f) HUVECs were treated with ARF6 inhibitor (NAV2729; 5 µM), ARNO inhibitor (Secin H3; 10 µM), or dimethyl sulfoxide (DMSO) as vehicle control at the same time as eVape exposure. (c) ROS accumulation was assessed by DCFDA incorporation (fluorescence at 485/535 nm) following 2 h of treatment. (d) Cell adhesion, (e) migration, and (f) angiogenic potential were measured following (d, e) 6 h and (f) 24 h of treatments. (g) Protein expression of (i) angiopoietin-2, (ii) EGF, (iii) endoglin, (iv) PIGF, (v) prolactin, and (vi) VEGF were measured using specific ELISA arrays following 24 h of treatment with 2% nicotine-free eVape fluid in the presence (closed circles) and absence (open circles) of Secin H3 (10 µM). The data are presented as mean ± SEM, n = 5–6. * p < 0.05 versus vehicle for eVape (0%); # p < 0.05 versus vehicle for NAV2729 and Secin H3 (DMSO).

Journal: Frontiers in Toxicology

Article Title: Nicotine-free electronic vape fluid stimulates angiogenic processes in vitro through ARF6-mediated oxidative stress

doi: 10.3389/ftox.2025.1699112

Figure Lengend Snippet: Activation of ARF6 by its guanine nucleotide exchange factor (ARNO) regulates angiogenic processes in endothelial cells induced by nicotine-free eVape. (a, b) HUVECs were exposed to 2% nicotine-free eVape fluid for 24 h, and the cell lysates were analysed by Western blotting for (a) ARF6 or (b) ARNO expression. The Western blotting membranes (representative blots are shown in (i) ) were quantified and normalised to the actin expression shown in (ii) . (c–f) HUVECs were treated with ARF6 inhibitor (NAV2729; 5 µM), ARNO inhibitor (Secin H3; 10 µM), or dimethyl sulfoxide (DMSO) as vehicle control at the same time as eVape exposure. (c) ROS accumulation was assessed by DCFDA incorporation (fluorescence at 485/535 nm) following 2 h of treatment. (d) Cell adhesion, (e) migration, and (f) angiogenic potential were measured following (d, e) 6 h and (f) 24 h of treatments. (g) Protein expression of (i) angiopoietin-2, (ii) EGF, (iii) endoglin, (iv) PIGF, (v) prolactin, and (vi) VEGF were measured using specific ELISA arrays following 24 h of treatment with 2% nicotine-free eVape fluid in the presence (closed circles) and absence (open circles) of Secin H3 (10 µM). The data are presented as mean ± SEM, n = 5–6. * p < 0.05 versus vehicle for eVape (0%); # p < 0.05 versus vehicle for NAV2729 and Secin H3 (DMSO).

Article Snippet: NAV2729 and Secin H3 were purchased from Tocris Bioscience (Abingdon, UK); Proteome Profiler Human angiogenesis array and enzyme-linked immunosorbent assay (ELISA) kits for human angiopoietin-2 (DANG20), endothelial growth factor (EGF; DEG00), endoglin (DNDG00), placental growth factor (PIGF; DPG00), prolactin (DY682), and vascular endothelial growth factor (VEGF; DVE00) were all obtained from R&D Systems (Abingdon, UK).

Techniques: Activation Assay, Western Blot, Expressing, Control, Fluorescence, Migration, Enzyme-linked Immunosorbent Assay

Figure 2. Cytotoxicity of d‑2HG in BAECs. (A and B) BAECs were treated with various concentrations of d‑2HG (25 µM to 50 mM) for 24 h (A) or 48 h (B). Cell viability was measured by CCK‑8 assays. VEGF (40 ng/ml) was used as a positive control. *P<0.05 versus the control. BAECs, bovine aortic endothelial cells; d‑2HG, d‑2‑hydroxyglutarate; VEGF, vascular endothelial growth factor.

Journal: International journal of oncology

Article Title: The oncometabolite d‑2‑hydroxyglutarate induces angiogenic activity through the vascular endothelial growth factor receptor 2 signaling pathway.

doi: 10.3892/ijo.2018.4649

Figure Lengend Snippet: Figure 2. Cytotoxicity of d‑2HG in BAECs. (A and B) BAECs were treated with various concentrations of d‑2HG (25 µM to 50 mM) for 24 h (A) or 48 h (B). Cell viability was measured by CCK‑8 assays. VEGF (40 ng/ml) was used as a positive control. *P<0.05 versus the control. BAECs, bovine aortic endothelial cells; d‑2HG, d‑2‑hydroxyglutarate; VEGF, vascular endothelial growth factor.

Article Snippet: The amount of VEGF protein secreted by the A549 human lung cancer cells into the medium was determined using a VEGF ELISA kit (R&D Systems, Wiesbaden, Germany).

Techniques: Positive Control, Control

Figure 3. d‑2HG increases VEGF secretion and the proliferation of BAECs. (A) A549 cells were starved for 16 h in 0.5% FBS‑containing medium, treated with

Journal: International journal of oncology

Article Title: The oncometabolite d‑2‑hydroxyglutarate induces angiogenic activity through the vascular endothelial growth factor receptor 2 signaling pathway.

doi: 10.3892/ijo.2018.4649

Figure Lengend Snippet: Figure 3. d‑2HG increases VEGF secretion and the proliferation of BAECs. (A) A549 cells were starved for 16 h in 0.5% FBS‑containing medium, treated with

Article Snippet: The amount of VEGF protein secreted by the A549 human lung cancer cells into the medium was determined using a VEGF ELISA kit (R&D Systems, Wiesbaden, Germany).

Techniques:

Figure 4. d‑2HG increased migration and tube formation ability in BAECs. (A) BAECs (90% confluence) were starved with 0.5% FBS in DMEM/low glucose for 16 h and treated with mitomycin C (1 µg/ml) for 1 h. The cells were scratched with a 1‑ml micropipette tip and incubated in starvation medium with VEGF (40 ng/ml) or d‑2HG (250 µM). Wound closure from the original location was monitored and graphed. *P<0.05 versus the control. (B) Transwell migration assays were performed in 24‑Transwell plates (6.5 mm diameter, 8 µm pore size membrane). BAECs were seeded in the upper chamber, and VEGF (40 ng/ml) and d‑2HG (250 µM) were added to the lower chambers for 24 h. Migrated cells were fixed with 100% methanol, stained with hematoxylin and eosin, and counted. *P<0.05 versus the control. (C) BAECs were starved in 0.5% FBS in DMEM/low glucose for 16 h, seeded (3x104 cells) on the surface of the Matrigel, and incubated for 8‑16 h with or without VEGF (40 ng/ml) or d‑2HG (250 µM) in DMEM/low glucose containing 0.5% FBS. Morphological changes were observed under a microscope and photographed at x100 magnification. The results are presented as the mean number of branching points. BAECs, bovine aortic endothelial cells; d‑2HG, d‑2‑hydroxyglutarate; VEGF, vascular endothelial growth factor.

Journal: International journal of oncology

Article Title: The oncometabolite d‑2‑hydroxyglutarate induces angiogenic activity through the vascular endothelial growth factor receptor 2 signaling pathway.

doi: 10.3892/ijo.2018.4649

Figure Lengend Snippet: Figure 4. d‑2HG increased migration and tube formation ability in BAECs. (A) BAECs (90% confluence) were starved with 0.5% FBS in DMEM/low glucose for 16 h and treated with mitomycin C (1 µg/ml) for 1 h. The cells were scratched with a 1‑ml micropipette tip and incubated in starvation medium with VEGF (40 ng/ml) or d‑2HG (250 µM). Wound closure from the original location was monitored and graphed. *P<0.05 versus the control. (B) Transwell migration assays were performed in 24‑Transwell plates (6.5 mm diameter, 8 µm pore size membrane). BAECs were seeded in the upper chamber, and VEGF (40 ng/ml) and d‑2HG (250 µM) were added to the lower chambers for 24 h. Migrated cells were fixed with 100% methanol, stained with hematoxylin and eosin, and counted. *P<0.05 versus the control. (C) BAECs were starved in 0.5% FBS in DMEM/low glucose for 16 h, seeded (3x104 cells) on the surface of the Matrigel, and incubated for 8‑16 h with or without VEGF (40 ng/ml) or d‑2HG (250 µM) in DMEM/low glucose containing 0.5% FBS. Morphological changes were observed under a microscope and photographed at x100 magnification. The results are presented as the mean number of branching points. BAECs, bovine aortic endothelial cells; d‑2HG, d‑2‑hydroxyglutarate; VEGF, vascular endothelial growth factor.

Article Snippet: The amount of VEGF protein secreted by the A549 human lung cancer cells into the medium was determined using a VEGF ELISA kit (R&D Systems, Wiesbaden, Germany).

Techniques: Migration, Incubation, Control, Pore Size, Membrane, Staining, Microscopy

Figure 6. d‑2HG induces VEGFR2 signaling pathway activation and MMP2 activity. (A) BAECs were treated with VEGF (40 ng/ml) or d‑2HG (250 µM) for 10 min, and protein lysates was obtained for western blot analysis. (B) Western blot analysis and gelatin zymography analyses for MMP2 and pro‑MMP2, respectively, were performed with medium obtained from the same samples as described in (A). The relative expression pattern of MMP2 was quantified and graphed below the gel images. *P<0.05 versus the control. (C) Schematic summary of the mechanism through which d‑2HG enhances angiogenesis.

Journal: International journal of oncology

Article Title: The oncometabolite d‑2‑hydroxyglutarate induces angiogenic activity through the vascular endothelial growth factor receptor 2 signaling pathway.

doi: 10.3892/ijo.2018.4649

Figure Lengend Snippet: Figure 6. d‑2HG induces VEGFR2 signaling pathway activation and MMP2 activity. (A) BAECs were treated with VEGF (40 ng/ml) or d‑2HG (250 µM) for 10 min, and protein lysates was obtained for western blot analysis. (B) Western blot analysis and gelatin zymography analyses for MMP2 and pro‑MMP2, respectively, were performed with medium obtained from the same samples as described in (A). The relative expression pattern of MMP2 was quantified and graphed below the gel images. *P<0.05 versus the control. (C) Schematic summary of the mechanism through which d‑2HG enhances angiogenesis.

Article Snippet: The amount of VEGF protein secreted by the A549 human lung cancer cells into the medium was determined using a VEGF ELISA kit (R&D Systems, Wiesbaden, Germany).

Techniques: Activation Assay, Activity Assay, Western Blot, Zymography, Expressing, Control

FIG. 1. Morphometry of the anatomical zones analyzed in this study: VF, VH, main CST, DREZ, and CC. The gray field represents the area im- mediately around the Ad5-VEGF+Ad5-ANG or Ad5-GFP injections.

Journal: Journal of Neurosurgery: Spine

Article Title: Post–spinal cord injury astrocyte-mediated functional recovery in rats after intraspinal injection of the recombinant adenoviral vectors Ad5-VEGF and Ad5-ANG

doi: 10.3171/2016.9.spine15959

Figure Lengend Snippet: FIG. 1. Morphometry of the anatomical zones analyzed in this study: VF, VH, main CST, DREZ, and CC. The gray field represents the area im- mediately around the Ad5-VEGF+Ad5-ANG or Ad5-GFP injections.

Article Snippet: Expression of VEGF protein was detected 24 hours postinfection by an enzyme immunoassay of the culture medium of 293 cells infected with recombinant adenovirus Ad5-VEGF at a dose of 5 plaque-forming units (PFUs) per cell using the Human VEGF QuantiGlo ELISA Kit (R&D Systems).

Techniques:

FIG. 2. Time course of BBB score changes following SCI. At 7 dpi, BBB scores decreased markedly to 0.6 ± 0.4 in the Ad5-VEGF+Ad5- ANG and 3.1 ± 0.4 in the Ad5-GFP groups. By 4 weeks after SCI, BBB scores gradually increased in both groups. The final BBB score in the Ad5-VEGF+Ad5-ANG group was 14.3 ± 0.8 whereas it was 8.4 ± 0.8 in the Ad5-GFP group. The asterisks indicate statistically significant dif- ferences between the Ad5-VEGF+Ad5-ANG and Ad5-GFP groups (p < 0.05, 1-way ANOVA).

Journal: Journal of Neurosurgery: Spine

Article Title: Post–spinal cord injury astrocyte-mediated functional recovery in rats after intraspinal injection of the recombinant adenoviral vectors Ad5-VEGF and Ad5-ANG

doi: 10.3171/2016.9.spine15959

Figure Lengend Snippet: FIG. 2. Time course of BBB score changes following SCI. At 7 dpi, BBB scores decreased markedly to 0.6 ± 0.4 in the Ad5-VEGF+Ad5- ANG and 3.1 ± 0.4 in the Ad5-GFP groups. By 4 weeks after SCI, BBB scores gradually increased in both groups. The final BBB score in the Ad5-VEGF+Ad5-ANG group was 14.3 ± 0.8 whereas it was 8.4 ± 0.8 in the Ad5-GFP group. The asterisks indicate statistically significant dif- ferences between the Ad5-VEGF+Ad5-ANG and Ad5-GFP groups (p < 0.05, 1-way ANOVA).

Article Snippet: Expression of VEGF protein was detected 24 hours postinfection by an enzyme immunoassay of the culture medium of 293 cells infected with recombinant adenovirus Ad5-VEGF at a dose of 5 plaque-forming units (PFUs) per cell using the Human VEGF QuantiGlo ELISA Kit (R&D Systems).

Techniques:

FIG. 4. Immunohistochemical staining of sections from the center of the lesion site with anti-GFAP (red), anti-S100b (yellow), and anti- AQP4 (green) antibodies to label astrocytes in the CC 30 days after administration of Ad5-VEGF+Ad5-ANG (A, C, and E) and Ad5-GFP (B, D, and F). There was increased GFAP immunoreactivity in the Ad5- VEGF+Ad5-ANG group compared with the Ad5-GFP group. The size of the perikaryon of astrocytes expressing S100b and GFAP was larger in the Ad5-VEGF+Ad5-ANG group than in the Ad5-GFP group. Nuclei were counterstained with DAPI. All images were obtained by confocal microscopy. Scale bar = 20 µm. Figure is available in color online only.

Journal: Journal of Neurosurgery: Spine

Article Title: Post–spinal cord injury astrocyte-mediated functional recovery in rats after intraspinal injection of the recombinant adenoviral vectors Ad5-VEGF and Ad5-ANG

doi: 10.3171/2016.9.spine15959

Figure Lengend Snippet: FIG. 4. Immunohistochemical staining of sections from the center of the lesion site with anti-GFAP (red), anti-S100b (yellow), and anti- AQP4 (green) antibodies to label astrocytes in the CC 30 days after administration of Ad5-VEGF+Ad5-ANG (A, C, and E) and Ad5-GFP (B, D, and F). There was increased GFAP immunoreactivity in the Ad5- VEGF+Ad5-ANG group compared with the Ad5-GFP group. The size of the perikaryon of astrocytes expressing S100b and GFAP was larger in the Ad5-VEGF+Ad5-ANG group than in the Ad5-GFP group. Nuclei were counterstained with DAPI. All images were obtained by confocal microscopy. Scale bar = 20 µm. Figure is available in color online only.

Article Snippet: Expression of VEGF protein was detected 24 hours postinfection by an enzyme immunoassay of the culture medium of 293 cells infected with recombinant adenovirus Ad5-VEGF at a dose of 5 plaque-forming units (PFUs) per cell using the Human VEGF QuantiGlo ELISA Kit (R&D Systems).

Techniques: Immunohistochemical staining, Staining, Expressing, Confocal Microscopy

FIG. 6. Confocal immunofluorescence showing the association of the oligodendrocyte precursor marker NG2 with the pan-oligo- dendrocyte marker OLIG2 in imaging fields showing the area around the CC 30 days after administration of Ad5-VEGF+Ad5-ANG (A–C) or Ad5-GFP (D–F). The images indicate that there was increased OLIG2 (green) and NG2 (red) immunoreactivity in the Ad5-VEGF+Ad5-ANG group (A and B) compared with the Ad5-GFP group (D and E). Note that NG2 fibers and oligodendrocyte cell bodies (OLIG2+ cells) are colocalized (C and F). Nuclei were counterstained with DAPI. Scale bar = 20 µm. Figure is available in color online only.

Journal: Journal of Neurosurgery: Spine

Article Title: Post–spinal cord injury astrocyte-mediated functional recovery in rats after intraspinal injection of the recombinant adenoviral vectors Ad5-VEGF and Ad5-ANG

doi: 10.3171/2016.9.spine15959

Figure Lengend Snippet: FIG. 6. Confocal immunofluorescence showing the association of the oligodendrocyte precursor marker NG2 with the pan-oligo- dendrocyte marker OLIG2 in imaging fields showing the area around the CC 30 days after administration of Ad5-VEGF+Ad5-ANG (A–C) or Ad5-GFP (D–F). The images indicate that there was increased OLIG2 (green) and NG2 (red) immunoreactivity in the Ad5-VEGF+Ad5-ANG group (A and B) compared with the Ad5-GFP group (D and E). Note that NG2 fibers and oligodendrocyte cell bodies (OLIG2+ cells) are colocalized (C and F). Nuclei were counterstained with DAPI. Scale bar = 20 µm. Figure is available in color online only.

Article Snippet: Expression of VEGF protein was detected 24 hours postinfection by an enzyme immunoassay of the culture medium of 293 cells infected with recombinant adenovirus Ad5-VEGF at a dose of 5 plaque-forming units (PFUs) per cell using the Human VEGF QuantiGlo ELISA Kit (R&D Systems).

Techniques: Immunofluorescence, Marker, Imaging

FIG. 7. Quantitative RT-PCR of S100b gene expression. RT-PCR as- says at 30 dpi revealed a significant reduction in S100b mRNA expres- sion normalized to S18 in the Ad5-VEGF+Ad5-ANG group (18-fold) and the Ad5-GFP group (34-fold) compared with the intact spinal cord. By 1-way ANOVA, p values were < 0.01 between all groups (intact spinal cord, Ad5-VEGF+Ad5-ANG, and Ad5-GFP).

Journal: Journal of Neurosurgery: Spine

Article Title: Post–spinal cord injury astrocyte-mediated functional recovery in rats after intraspinal injection of the recombinant adenoviral vectors Ad5-VEGF and Ad5-ANG

doi: 10.3171/2016.9.spine15959

Figure Lengend Snippet: FIG. 7. Quantitative RT-PCR of S100b gene expression. RT-PCR as- says at 30 dpi revealed a significant reduction in S100b mRNA expres- sion normalized to S18 in the Ad5-VEGF+Ad5-ANG group (18-fold) and the Ad5-GFP group (34-fold) compared with the intact spinal cord. By 1-way ANOVA, p values were < 0.01 between all groups (intact spinal cord, Ad5-VEGF+Ad5-ANG, and Ad5-GFP).

Article Snippet: Expression of VEGF protein was detected 24 hours postinfection by an enzyme immunoassay of the culture medium of 293 cells infected with recombinant adenovirus Ad5-VEGF at a dose of 5 plaque-forming units (PFUs) per cell using the Human VEGF QuantiGlo ELISA Kit (R&D Systems).

Techniques: Quantitative RT-PCR, Gene Expression, Reverse Transcription Polymerase Chain Reaction